Activity Overview
In recent years, the applicability of novel therapies to manage acute myeloid leukemia (AML) has expanded dramatically, offering new opportunities to achieve disease control in select patients. However, this has also increased the demands on health care professionals to keep pace with a rapidly expanding arsenal of treatment options. In particular, adequate testing, treatment selection, and the management of adverse events have continued to evolve at a rapid pace.
This meeting series is designed in conjunction with expert faculty in the management of AML to distill the evolving best practices for a community of oncology professionals who treat many different forms of cancer. It features key updates from clinical trials and is supplemented by illustrative case presentations presented by community oncology moderators.
This educational activity is an archive of the live presentation held on April 21, 2026.
Target Audience
This educational program is primarily directed toward community-based medical oncologists/hematologists, oncology nurses, advanced practice providers, and other health care professionals involved in the treatment of AML.
Learning Objectives
At the conclusion of this activity, you should be better prepared to:
- Implement personalized care plans for patients with AML aligned with guideline-recommended molecular testing and risk stratification protocols
- Assess emerging strategies for the management of patients with AML in the frontline and relapsed/refractory setting
- Devise effective strategies to monitor for and manage treatment-associated adverse events in patients with AML
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here